3 not yet recruiting, 2 recruiting, 1 completed, 1 unknown. 3 Phase 2, 2 Phase 1, 1 Early Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Not yet recruiting 1, Recruiting 1, Unknown 1 |
| Phase 1 | 2 | Completed 1, Not yet recruiting 1 |
| Early Phase 1 | 1 | Not yet recruiting 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Cutaneous T Cell Lymphoma (CTCL): new trials by email Literature Review of Cutaneous T Cell Lymphoma (CTCL) trials Research Report on Cutaneous T Cell Lymphoma (CTCL)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma Aclarubicin, Cyclophosphamide, Vincristine - Cutaneous T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma, Relapsed | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Jiao Tong University School of Medicine | 37 | 2026-03-30 | 2026-04-17 |
| A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL) DT-7012 - Cutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides | Early Phase 1 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 30 | 2026-01-01 | 2025-10-09 |
| Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance Brentuximab Vedotin (Bv), Placebo - Cutaneous T Cell Lymphoma (CTCL), Brentuximab Vedotin | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 84 | 2025-11-01 | 2025-09-17 |
| JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas JAK1 Inhibitor - Lymphoma, T-Cell, NK-LGL Leukemia | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 48 | 2024-12-25 | 2025-11-18 |
| Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) IL-15 plus, alemtuzumab - T-Cell Lymphoma Relapsed, Adult T-Cell Leukemia (ATL) | Phase 1 | Completed | National Cancer Institute (NCI) | 11 | 2017-01-19 | 2022-04-29 |
| NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT) NM-IL-12 and TSEBT - Cutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides | Phase 2 | Unknown | Neumedicines Inc. | 10 | 2015-12-01 | 2018-11-16 |
| Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment Hairy Cell Leukemia (HCL), Chronic Lymphocytic Leukemia (CLL) | Recruiting | National Cancer Institute (NCI) | 1263 | 2010-03-02 | 2026-10-16 |
Lymphoma, T-Cell, Cutaneous (7) · Mycosis Fungoides (3) · Sezary Syndrome (3) · Hemolytic-Uremic Syndrome (1) · Leukemia, Hairy Cell (1) · Leukemia, Large Granular Lymphocytic (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Prolymphocytic, T-Cell (1) · Leukemia-Lymphoma, Adult T-Cell (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell (1) · Lymphoma, T-Cell, Peripheral (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1)
Hemic and Lymphatic Diseases (7) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Lymphatic Diseases (7) · Lymphoma (7) · Lymphoproliferative Disorders (7) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Lymphoma, Non-Hodgkin (6) · Lymphoma, T-Cell (6) · Hematologic Diseases (3) · Leukemia (3) · Leukemia, Lymphoid (3) · Disease Attributes (2) · Leukemia, T-Cell (2)
Aclarubicin (1) · Alemtuzumab (1) · Brentuximab Vedotin (1) · Cyclophosphamide (1) · Interleukin-12 Subunit p35 (1) · Interleukin-15 (1) · Prednisone (1) · Vincristine (1)
Assistance Publique - Hôpitaux de Paris (2) · National Cancer Institute (NCI) (2) · Institute of Hematology & Blood Diseases Hospital, China (1) · Neumedicines Inc. (1) · Shanghai Jiao Tong University School of Medicine (1)
United States (3) · China (2)
Junmin Li, Professor (1) · Kevin Conlon, M.D. (1) · Robert J Kreitman, M.D. (1) · Youn H Kim, MD (1)
PMID 32508818, PMID 33883258, PMID 35475910, PMID 37729613, PMID 37877800, PMID 39719040, PMID 40552139
R44CA192576 (1)